Cardio Total Revenue from 2010 to 2025

CDIO Stock  USD 0.47  0.03  5.50%   
Cardio Diagnostics Total Revenue yearly trend continues to be very stable with very little volatility. Total Revenue is likely to grow to about 20.6 K this year. Total Revenue is the total amount of income generated by the sale of goods or services related to Cardio Diagnostics' primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
19.6 K
Current Value
20.6 K
Quarterly Volatility
7.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cardio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardio Diagnostics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 134.8 K or Selling General Administrative of 8.4 M, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or PTB Ratio of 11.67. Cardio financial statements analysis is a perfect complement when working with Cardio Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Cardio Diagnostics Correlation against competitors.

Latest Cardio Diagnostics' Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Cardio Diagnostics Holdings over the last few years. Total revenue comprises all receipts Cardio Diagnostics generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Cardio Diagnostics' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
901.950.17.119.620.65%1696%15%5%100%
       Timeline  

Cardio Total Revenue Regression Statistics

Arithmetic Mean3,697
Geometric Mean0.00
Coefficient Of Variation207.67
Mean Deviation5,776
Median0.00
Standard Deviation7,677
Sample Variance58.9M
Range20.6K
R-Value0.70
Mean Square Error32.3M
R-Squared0.49
Significance0
Slope1,128
Total Sum of Squares884M

Cardio Total Revenue History

202520.6 K
202419.6 K
202317.1 K
2022 950.0
2021 901.0

About Cardio Diagnostics Financial Statements

Cardio Diagnostics investors utilize fundamental indicators, such as Total Revenue, to predict how Cardio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue19.6 K20.6 K

Pair Trading with Cardio Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cardio Stock

  0.75XFOR X4 PharmaceuticalsPairCorr

Moving against Cardio Stock

  0.34KURA Kura Oncology Earnings Call TodayPairCorr
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cardio Diagnostics is a strong investment it is important to analyze Cardio Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardio Diagnostics' future performance. For an informed investment choice regarding Cardio Stock, refer to the following important reports:
Check out the analysis of Cardio Diagnostics Correlation against competitors.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.30)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.34)
Return On Assets
(1.00)
Return On Equity
(2.76)
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

ELEV
Elevation Oncology
0.56  -0.03  -4.83 
EFTR
Effector Therapeutics
0.00  0.00  0.00 
PHIO
Phio Pharmaceuticals Corp
1.45  -0.12  -7.64 
ZURA
Zura Bio Limited
1.27  -0.13  -9.29 
NAVB
Navidea Biopharmaceutica
0.00  0.00  0.00 
ATNF
180 Life Sciences
1.23  -0.02  -1.6 
CYTO
Altamira Therapeutics
0.00  0.00  0.00 
SONN
Sonnet Biotherapeutics
1.51  0.07  4.86 
AVRO
AVRO Old
0.00  0.00  0.00 
VECT
VectivBio Holding
0.00  0.00  0.00 
ZVSA
ZyVersa Therapeutics
1.10  -0.02  -1.79 
PYXS
Pyxis Oncology
1.22  -0.06  -4.69 
CNSP
Cns Pharmaceuticals
2.33  -0.55  -19.1 
IMMX
Immix Biopharma
1.66  -0.06  -3.49 
News Freq…Investor S…